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Abstract
Identifying functional modules or novel active pathways, recently termed de
novo pathway enrichment, is a computational systems biology challenge that
has gained much attention during the last decade. Given a large biological
interaction network, KeyPathwayMiner extracts connected subnetworks that
are enriched for differentially active entities from a series of molecular profiles
encoded as binary indicator matrices. Since interaction networks constantly
evolve, an important question is how robust the extracted results are when the
network is modified. We enable users to study this effect through several
network perturbation techniques and over a range of perturbation degrees. In
addition, users may now provide a gold-standard set to determine how
enriched extracted pathways are with relevant genes compared to randomized
versions of the original network.
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Introduction
De novo pathway enrichment methods have gained much atten-
tion during the last decade due to their potential to identify novel 
regulators and putative biomarkers from vast datasets in systems 
biology research. Given a biological interaction network, such 
as defined by BioGrid1, IntAct2 or I2D3, the main objective of 
de novo pathway enrichment is to extract connected subnetworks 
that are enriched for genes that are implicated in the phenotype 
of interest. This phenotype is dependent on the experiment and 
observed in one or several omics datasets, including, for instance, 
gene expression values, DNA methylation signals or single nucle-
otide variants. The common denominator of de novo pathway 
enrichment methods is that the resulting subnetworks are expected 
to include known pathways as well as novel pathways that have 
little overlap with annotated pathways found in curated databases. 
Existing approaches can be divided into the following categories: 
(i) aggregate score optimization methods, where the objective is to 
extract subnetworks that maximize a summary or statistical score 
of the individual gene scores, (ii) score propagation methods, where 
individual gene scores from the molecular profiles are propagated 
through the network, or adjusted to reflect also their connectivity 
in the network, (iii) module cover approaches, where the objec-
tive is to extract subnetworks containing genes that cover as many 
active cases/samples as possible, and (iv) cluster-based approaches. 
Methods that fall into categories (i), (ii) or (iv) rely heavily on the 
scoring function, which must be appropriate for the technology 
of the molecular profile being studied. In contrast, methods based 
on the module cover approach (iii) do not suffer from this issue, 
but leave it up to the user to find a sensible way to discern active 
from inactive genes. An overview of popular de novo pathway 
enrichment methods is shown in Table 1. We identify three issues 
common to existing de novo methods: 
• There is little consensus on what constitutes a novel path-
way. It is up to the user to find method-specific parameters 
that lead to a satisfying solution. Choosing these parameters 
is often not intuitive and even small changes can lead to 
large variations in the results. Most methods provide little 
guidance on parameter selection, forcing users to rely on 
educated guesses, or to tediously re-run the method multiple 
times until the optimal parameters for a given analysis are 
found.
• It has been demonstrated that for several methods results 
change significantly upon perturbations in the underly-
ing networks4. This lack of robustness is an issue, since 
interaction databases are continuously evolving and it 
is unclear to what degree the results will change when a 
particular tool is applied with the exact same data to a newer 
version of the network.
• In the rare cases where a ground truth or gold standard is 
available, the validation of de novo pathway enrichment 
results is not straightforward and, to our knowledge, not 
supported by any available method.
We have previously developed KeyPathwayMiner, a de novo 
pathway enrichment tool following the module cover approach. 
Even though the parameters in KeyPathwayMiner are relatively 
intuitive, their selection becomes challenging for analyses involv-
ing several distinct omics datasets. To address this issue, we allow 
users to define a range (consisting of minimum, maximum and 
step size) for each parameter. The resulting grid search is fully 
automated and saves the user from going through tedious rep-
etitions. While testing different parameters is more convenient 
in this way, it is still necessary to manually inspect the resulting 
subnetworks to select the optimal settings in a subjective fashion.
Here, we present version 5 of KeyPathwayMiner, which is the 
first tool to provide a user-friendly way to systematically evalu-
ate the quality and robustness of the results in de novo pathway 
enrichment. We achieve this by perturbing the input network to 
Table 1. A non-exhaustive selection of popular de novo network 
enrichment tools. Abbreviations: Cytoscape app (CA), standalone version/
package (SA), desktop application (DA), web application (WA), web service 
(WS), visualization (VIZ), multi-omics (MO), robustness of the results upon 
network perturbation (RB), validation of the results using a gold standard 
upon network perturbation (VL).
CA SA DA WA WS VIZ MO RB VL
BioNET5 ✘ ✔ ✘ ✘ ✘ ✔ ✘ ✘ ✘
GiGa6 ✘ ✔ ✘ ✘ ✘ ✘ ✘ ✘ ✘
GXNA7 ✘ ✔ ✘ ✘ ✘ ✘ ✘ ✘ ✘
HotNet8 ✘ ✔ ✘ ✘ ✘ ✔ ✘ ✘ ✘
jActiveModules9 ✔ ✘ ✘ ✘ ✘ ✔ ✘ ✘ ✘
MATISSE10 ✘ ✘ ✔ ✘ ✘ ✔ ✘ ✘ ✘
PinnacleZ11 ✔ ✘ ✘ ✘ ✘ ✔ ✘ ✘ ✘
RegMOD12 ✘ ✔ ✘ ✘ ✘ ✘ ✘ ✘ ✘
KPM 5.0 ✔ ✔ ✘ ✔ ✔ ✔ ✔ ✔ ✔
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varying degrees. Depending on the research question, several 
perturbation techniques are available. To assess robustness of the 
results, the largest solution found in the perturbed network(s) is 
compared against the largest solution found in the unperturbed 
network. The size and variance of the overlap is illustrated for 
different user-controlled levels of perturbation and is an indicator 
for the robustness of the results. If a gold standard is available, an 
additional measure of quality is the overlap of the largest solution 
found in the unperturbed as well as in the perturbed network(s) 
with the gold standard. As an example application case, we apply 
KeyPathwayMiner to a gene expression dataset covering 38 
Huntington’s disease patients and 32 healthy controls. We demon-
strate the potential of network perturbation to help assessing the 
quality and robustness of the extracted results.
Methods
Implementation
KeyPathwayMiner is implemented as a modular Java applica-
tion centering on a core module that provides various de novo 
pathway enrichment strategies and methods for network perturba-
tion analysis and plotting. A number of application modules have 
been implemented for different usage scenarios, including a stan-
dalone module, a web application module13, and a Cytoscape app 
module. The web application module KeyPathwayMinerWeb 
(http://keypathwayminer.compbio.sdu.dk), for instance, is primarily 
targeted at researchers with little to no experience in Cytoscape. 
No installation is necessary and convenience features, such as the 
mapping of identifiers or the conversion of p-value matrices to 
indicator matrices, are included. Web application developers may 
utilize a RESTful interface to integrate KeyPathwayMinerWeb 
seamlessly into their own applications. The standalone version is 
targeted at developers and data analysts who need more compu-
tational power than KeyPathwayMinerWeb offers and thus seek 
to incorporate KeyPathwayMiner directly in their own software 
implementation or in data analysis scripts, respectively. Finally, 
the Cytoscape app is the most powerful module, since it is also 
not limited with respect to the parameter range and computational 
power needed but also offers additional useful features such as 
combining OMICs datasets with a logical formula editor or the gen-
eration of plots using the JFreeChart (www.jfreechart.org) library.
Operation
After installing the KeyPathwayMiner Cytoscape app via the app 
store, the user is expected to load an interaction network into 
Cytoscape. The KeyPathwayMiner tab can be found in the Control 
Panel and allows for one or more indicator matrices to be selected 
as input under the initial tab ‘Data’. These matrices can be derived 
from OMICs datasets such that samples correspond to columns 
and nodes (genes) to rows. Each entry in the matrix is either a ‘1’ 
indicating an active case in a node or ‘0’ otherwise. A typical 
example is a gene expression dataset in which a ‘1’ represents a 
differentially expressed gene. Another example could be a next- 
generation sequencing dataset where a ‘1’ indicates a single nucle-
otide polymorphism. Example files can be downloaded from the 
KeyPathwayMiner website at http://keypathwayminer.compbio.
sdu.dk (Figure 1A). In the next tab, called ‘Links’, the user can 
customize how several datasets are combined for the analysis. 
Here, one can choose between ‘AND’ (a case is considered active 
if it is active in all datasets), ‘OR’ (a case is considered active if it 
is active in any of the datasets), or ‘CUSTOM’, which allows for 
connecting datasets in an interactive formula editor (Figure 1B). 
The tab ‘Pos/Neg’ allows the user to define nodes that are always 
considered active (positive list) or that are ignored (negative list). 
In the ‘Run’ tab, it is finally possible to select the parameters for 
the KeyPathwayMiner run. Batch runs can also be performed by 
defining a range of values for K and L, such that users can conven-
iently run and assess the results for varying values of these parame-
ters. (Figure 1C). KeyPathwayMiner relies on two easy-to-interpret 
parameters to control the size of the extracted subnetworks. The 
user can choose between a local as well as a global enrichment 
strategy. In the local strategy, INEs (Individual Node ExceptionS), 
a gene is considered active when it is active in all but L cases/ 
samples. In addition, a parameter K allows KeyPathwayMiner to 
add additional inactive genes to extend the size of the solutions. We 
observe that INES has a tendency to prefer hub nodes, which is not 
always desirable. We therefore implemented the GLONE (GLobal 
Node Exceptions) strategy, where the parameter L is considered 
across all genes and fewer hub nodes are selected at the cost of 
run-time.
The optimal values for K and L depend on the dataset14. KeyPath-
wayMiner allows users to define a range for both parameters to 
identify the best settings in a straight-forward fashion.
Users can choose between different methods to extract sub-
networks: an exact (fixed parameter tractable), a greedy, and a 
heuristic (ant colony optimization) algorithm. For additional 
details regarding KeyPathwayMiner we refer to14–16.
Several new features have been implemented in version 5 of 
KeyPathwayMiner and are described in the following.
Network perturbation
KeyPathwayMiner now enables users to study the robustness 
and validity of the extracted subnetworks through perturbation 
(Figure 1D). To this end, the user can choose from the following 
common strategies: 
• Node label permutation: Pairs of nodes are selected 
arbitrarily and their node labels are swapped. This technique 
preserves the network structure exactly, but affects the local 
density of active genes in the network.
• Degree preserving rewiring: In this strategy first suggested 
by Maslov et al.17, two arbitrary edges are selected and their 
endpoints are swapped. As a result, the local network struc-
ture is actively changed while the global topological structure 
and the node degree distribution remain intact. With a large 
number of permutations this strategy leads to a randomized 
network.
• Node removal: In this strategy, a certain percentage of ar-
bitrarily selected nodes are removed, thus simulating what 
results on a less complete network would look like. This is 
particularly interesting since interaction networks are con-
tinuously growing in size.
• Edge removal: In contrast to node removal, which affects 
network size, this strategy affects primarily the density of a 
network.
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Figure 1. The user interface of the KeyPathwayMiner Cytoscape app is located in the control panel. The user sets the analysis up as 
follows (omitting the ‘Pos/Neg’ tab, where nodes can be specified for inclusion or exclusion): (A) one or several dataset files are selected from 
the disk. (B) Several dataset files can be logically connected via a formula editor. (C) The run parameters are configured, most importantly 
the enrichment strategy (INES or GLONE), the search algorithm, the input network and the search parameters K and/or L, which can also be 
defined as a range. (D) Network perturbation settings used in robustness or validation runs.
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Robustness analysis
To assess the quality of the results, we consider the overlap of 
the largest solution between the various perturbed and the non- 
perturbed analyses. With an increasing degree of perturbation of the 
network, it can be expected that this overlap will decrease. Users 
can thus assess how robust the observed result is by considering 
the Jaccard similarity coefficient between the gene sets Sperturbed 
and S
unperturbed based on the gene sets extracted from the largest 
solution found using the perturbed and non-perturbed networks, 
respectively: 
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Validation analysis
Similarly, the comparison of the overlap of the largest solution 
of the perturbed as well as the non-perturbed analyses and a gold 
standard SGold can be used as a quality metric: 
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New L parameter specification options
As a convenience feature, we now allow users to select L, which 
allows users to define the number of case exceptions allowed in a 
solution, to be defined as a percentage of the total number of cases. 
This is particularly advantageous in the case of multiple datasets, 
where the L parameter (range) can now be selected once for all 
datasets in spite of differences in the number of cases between 
them.
Border exception node removal
The INES model extracts subnetworks with up to K exception 
nodes that are not active or differentially expressed (as defined by 
the L parameter). In many cases, these exception nodes are cen-
tral in the pathway, i.e. they connect (groups of) active genes. 
However, if the K parameter is too large, some of these exception 
nodes are simply added to the periphery of the subnetwork 
to increase the size of the solution (Figure 2). As a result, the 
top solutions of a KeyPathwayMiner run would sometimes 
consist of overlapping subnetworks that only differ in these 
border exception nodes (BENs). BENs can now be removed in an 
optional filtering step, which will lead to more diverse solutions.
BENs are removed as shown in Algorithm 1, which has worst- 
case running time of O((|V | + |E|) ∗ K).
Algorithm 1. Border exception node filter
    Input: Graph G(V, E), Exception Nodes Ve ⊂ V
    Output: Subgraph G′ ⊆ G without BENs
    G′ := G ;
    while Ve ≠  do
         Vben :=  ;
         v := select and remove random node from Ve ;
         Ev := edges incident to v ;
         Gtemp := G′(V \ {v}, E \ Ev) ;
         C := connected components of Gtemp ;
         s := 0 ;
         foreach c ∈ C do
              if V(c) ∩ Ve == V(c) then
                   Vben := Vben ∪ V(c)
              else
                   s := s + 1 ;
              end
         end
         if s == 1 then
              Vben := Vben ∪ {v}
         end
         Ve := Ve \ Vben ;
         Eben := edges incident to Vben in G′ ;
         G′ := G′(V \ Vben, E \ Eben) ;
    end
    return G′ ;
Figure 2. Three putative examples of solutions obtained with K = 3 exception nodes to illustrate the impact of border exception nodes 
(BENs). Removing BENs (red) would not disconnect regions containing no exception nodes (white). In contrast, removing non-BEN exception 
nodes (dark grey) would create two disjoint subnetworks containing non-exception nodes.
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Use cases
We tested the usability of the new KeyPathwayMiner features with 
a gene expression dataset consisting of tissue samples from the 
caudate nucleus region of the brain18 taken from 38 patients suffer-
ing from Huntington’s disease (HD) and from 32 healthy patients 
in the control group. While it is known that huntingtin protein 
plays a major role in the development of the disease, the corre-
sponding gene is not differentially expressed in approximately 
40% of the patients. Hence, it will not be found in an analysis 
focused on identifying differentially expressed genes. However, 
it can be expected that protein-protein interaction (PPI) partners 
of the huntingtin protein are differentially expressed on the tran-
script level, thus posing an ideal test case for KeyPathwayMiner, 
which can identify subnetworks with huntingtin as an exception 
node. The Human Protein Reference Database (HPRD version 9, 
http://www.hprd.org/download)19 was used as the interaction 
network. To produce an indicator matrix for down-regulation, a 
one-tailed t-test was used to compute p-values for each gene and 
patient in the disease group vs all patients in the control group. 
Afterwards, a p-value cutoff of 0.05 was selected to set a 1 (sig-
nificant) or 0 (not significant) in the indicator matrix for down- 
regulation (file available at http://keypathwayminer.compbio.sdu.
dk/downloads/matrix-hd-down.dat).
In a first use case we performed a robustness analysis with 
KeyPathwayMiner (INES model, greedy algorithm) by fix-
ing parameters to L = 20% (8 out of 32) of the cases and K = 5 
exception nodes. In other words, we searched for maximal con-
nected subgraphs containing at most 5 nodes with no more than 
20% of cases in which the gene represented by the network node is 
not down-regulated.
In a typical robustness scenario, we wanted to test how the solu-
tions change when a certain percentage of the edges in the graph 
are removed randomly. We thus selected “edge removal” as the 
perturbation technique with perturbation levels selected to range 
from 10% to 50% in increments of 10%. For each perturbation 
level, we created 10 randomly perturbed networks and executed 
KeyPathway Miner with identical settings as in the original run.
As one would expect, removing a certain percentage of edges 
reduced the overlap with the results from the original network. 
However, even after removing 50% of the edges (Figure 3), a mod-
erate Jaccard index overlap of 0.45 was observed.
In a second use case, we give an example of a validation run. To 
this end, we compiled a gold standard gene set consisting of HD 
relevant genes (file available at http://keypathwayminer.compbio.
sdu.dk/downloads/htt-relevant.txt) from the KEGG20,21 HD and cal-
cium signaling pathways. Calcium signaling has been suggested 
to have an important role in the development of HD22.
In this scenario we wanted to see how solutions overlap with 
gold standard gene sets when randomly shuffling the node labels. 
In addition to the indicator matrix for down-regulation, we also 
aimed at finding solutions containing up-regulated genes. Hence 
we produced an additional indicator matrix for up-regulation 
(file available at http://keypathwayminer.compbio.sdu.dk/down-
loads/matrix-hd-up.dat) and connected them both with an ‘OR’ 
operator. We set a common L = 15% for both sets together with 
K = 5. KeyPathwayMiner (INES model, greedy algorithm) thus 
searched for pathways containing at most five genes with at most 
L = 15% genes that are not differentially regulated. The perturba-
tion technique chosen was “node label permutation”. The results 
show that even when permuting 80% of the node labels the overlap 
with the gold standard set remains relatively stable. As expected, 
we can see a significant drop when all labels are permuted 
(Figure 4).
Figure 3. Robustness results for different percentages of edge removal. For each perturbation level, 10 different networks were generated 
randomly and submitted to KeyPathwayMiner for analysis. (Parameters: INES, greedy, K = 5, L = 20%)
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Dataset 1. Use case data of de novo pathway enrichment with 
KeyPathwayMiner 5
http://dx.doi.org/10.5256/f1000research
Data from use cases are provided. Please see text file for a 
description of each set of data.
Summary
De novo pathway enrichment is a powerful method for the analysis 
of one or several types of molecular profiles. In contrast to widely 
used gene set enrichment methods such as GSEA23, this methodol-
ogy is not limited to existing knowledge but suitable to uncover 
new functional modules. Results are extracted using large biologi-
cal interaction networks, which are incomplete and continuously 
evolve. It is typically unclear how future updates leading to an 
interaction network of higher quality will affect the currently 
obtained results. KeyPathwayMiner 5 enables users to study the 
robustness of their results by allowing them to introduce artifi-
cial noise into the underlying interaction networks. Moreover, an 
existing gold standard can be used to test how well the optimal solu-
tion can be recovered on these perturbed networks.
Figure 4. Overlap with the selected HD gold standard gene set with different percentages of permuted node labels in the input 
network. For each perturbation degree, 10 graphs were generated. (Parameters: INES, greedy, K = 5, L = 15%). Note that partial network 
perturbation and subsequent comparison with gold standard sets has limited meaning. Biological interaction networks are scale-free, i.e. 
robust to random perturbations. Of major importance for this effect are a small number of hub nodes. KeyPathwayMiner is able to recover 
subnetworks containing relevant genes connected to such hubs unless the hubs themselves are affected by the perturbation. This, however, 
is only the case when 100% of the network is perturbed (a randomized, true null model), explaining the performance drop we observe for this 
degree of perturbation.
Data availability
F1000Research: Dataset 1. Use case data of de novo pathway 
enrichment with KeyPathwayMiner 5, 10.5256/f1000research. 
9054.d12687124
Software availability
1. Software available from: http://apps.cytoscape.org/apps/
keypathwayminer
2. Latest source code: https://github.com/baumbachlab/
keypathwayminer-cytoscape3 https://github.com/baum-
bachlab/keypathwayminer-cytoscape3/archive/5.0.tar.gz 
(KeyPathwayMiner Cytoscape app source code) 
https://github.com/baumbachlab/keypathwayminer-core/
archive/5.0.tar.gz (KeyPathwayMiner core library source 
code)
3. Archived source code as at time of publication: Zenodo, 
Source codes de novo pathway enrichment with KeyPath-
wayMiner, doi: 10.5281/zenodo5573425
4. License: GPL v3
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